Completed PHASE3 INTERVENTIONAL NCT00002456

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease

Sponsor: Fred Hutchinson Cancer Center

Conditions Graft Versus Host Disease Leukemia Lymphoma

Interventions allogeneic bone marrow transplantation cyclosporine methotrexate

Updated 6 times since 2017 Last updated: Nov 28, 2011 Started: May 31, 1986 Completion: Apr 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002456, this PHASE3 trial focuses on Graft Versus Host Disease and Leukemia and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 6 times since 1986, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — May 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 1986

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fred Hutchinson Cancer Center

Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States